Severe cholestasis related to intraconazole for the treatment of onychomycosis.
We describe a case of prolonged cholestasis temporally associated with the use of itraconazole for onychomycosis. Peak bilirubin level of 32.0 mg/dl was documented approximately 2 months after discontinuation of the patient's itraconazole therapy, with symptoms of cholestasis persisting more than 1 month after the peak in bilirubin. Physicians should be aware of the potential for severe cholestasis associated with itraconazole usage.
Talwalkar
J A
JA
Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Soetikno
R E
RE
Carr-Locke
D L
DL
Berg
C L
CL
D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001663:Bilirubin / Q000097:blood; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced*; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects*; D008111:Liver Function Tests; D008297:Male; D014009:Onychomycosis / Q000188:drug therapy*
D000935:Antifungal Agents; D017964:Itraconazole; D001663:Bilirubin